NEW HAVEN >> Alexion Pharmaceuticals will lay off 210 employees in the coming weeks as part of restructuring that a spokeswoman said is necessary to support the company’s long-term plans. The ...

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development ...

Alexion Pharmaceuticals stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than 10% ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

What happened. Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) , a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from ...

Image source: TBIT via pixabay. Alexion Pharmaceuticals' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as ...

Investors in Alexion Pharmaceuticals, a biopharmaceutical company with a focus on rare diseases, received a double dose of good news earlier this week. The company just announced that European ...

Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data ...

Alexion Pharmaceuticals (NASDAQ:ALXN) stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased ...